Spots Global Cancer Trial Database for myeloid and monocytic leukemia
Every month we try and update this database with for myeloid and monocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291 | Hematologic Mal... | Romiplostim | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03670966 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a... | Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | NCT04526288 | Acute Myeloid L... Myelodysplastic... Myeloid Neoplas... | Allogeneic Hema... Liposome-encaps... | 18 Years - | Fred Hutchinson Cancer Center | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | NCT04195945 | Acute Myeloid L... Myeloid Neoplas... | Liposome-encaps... Cladribine Cytarabine Recombinant Gra... Mitoxantrone Questionnaire A... Quality-of-Life... | 18 Years - | Fred Hutchinson Cancer Center | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | NCT00831766 | Myelodysplastic... Acute Myeloid L... | Idarubicin Cytarabine Lenalidomide (R... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
